Ucl Technology Fund 2 Lp investment portfolio

Axovia Therapeutics Ltd develops gene‑therapy treatments for ciliopathies, with its lead program AXV101—a AAV9‑based therapy aimed at halting retinal degeneration in Bardet‑Biedl Syndrome patients carrying BBS1 mutations. The company targets rare‑disease patients requiring novel genetic interventions for retinal dystrophy.

Stanhope AI develops AI systems founded on the active inference framework that enable robots and other embodied devices to make autonomous, explainable decisions on low‑power edge hardware, particularly in situations where they have not been trained. Their products target robotics, autonomous machines and real‑world engineering applications.